Derm Cases · Dermatology / Rheumatology
OSCE — heliotrope rash and proximal weakness: dermatomyositis work-up and red flags
An 8-minute OSCE station on pathognomonic DM skin signs, myositis assessment, MSA-guided phenotypes (incl. MDA5), cancer screening, and first-line immunosuppression principles.
On this page
Study tools
Target exams
NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on pathognomonic DM skin signs, myositis assessment, MSA-guided phenotypes (incl. MDA5), cancer screening, and first-line immunosuppression principles.
Brief (to candidate)
A 55-year-old woman has a violaceous periorbital heliotrope rash, Gottron papules over the knuckles, shawl-sign erythema, and 4 weeks of progressive proximal arm and thigh weakness with difficulty rising from a chair. CK is 2200 U/L. You have 8 minutes to confirm the syndrome, plan investigations and initial management, and state malignancy and ILD red flags.
Candidate instructions
- Name pathognomonic cutaneous signs of DM.
- Assess muscle disease and key differentials (PM, IBM, IMNM, CLE).
- Plan core labs, MSA panel, EMG/MRI/biopsy strategy at high level.
- Mandate cancer screening and ILD evaluation.
- Outline first-line steroids + steroid-sparing therapy and skin care.
- Escalate for anti-MDA5 RP-ILD and bulbar/respiratory involvement.
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Recognition | Heliotrope, Gottron papules/sign, V-sign/shawl, holster sign, mechanic hands, nailfold capillary changes ± proximal weakness spectrum (including amyopathic DM)[2][1] |
| Work-up | CK/ALD/LDH/AST/ALT, ANA, myositis-specific antibodies (Mi-2, MDA5, TIF1-γ, NXP2, SAE, Jo-1 etc.), EMG/MRI, consider muscle/skin biopsy; EULAR/ACR classification framework awareness[1][5] |
| Phenotypes | Anti-MDA5: CADM, ulcers, RP-ILD high early mortality; anti-TIF1-γ/NXP2: higher cancer association; anti-synthetase: mechanic hands, arthritis, ILD[3][2] |
| Cancer screen | Adult DM: age-appropriate malignancy screening at diagnosis and serially (often 3–5 years) — CT CAP, age/sex-specific tests; higher yield if TIF1-γ+ or older adult[1][4] |
| ILD screen | Symptoms, PFTs, HRCT if risk (esp. MDA5/synthetase); do not wait for florid respiratory failure[3] |
| Treatment | Photoprotection + often hydroxychloroquine for skin; prednisolone ~1 mg/kg (± pulse methylpred for severe) + MTX/AZA/MMF; IVIG, rituximab, JAK inhibitors in refractory/selected; aggressive combo Rx for MDA5 RP-ILD in specialist centres[4][1] |
| Communication | Explain chronic autoimmune disease; urgent red flags (dyspnoea, dysphagia, aspiration); multidisciplinary derm-rheum-resp-oncology |
Model key actions
- Identify classic DM cutaneous signs with proximal myopathy.[2]
- Order MSA panel, cancer screen, and ILD assessment; do not treat as "eczema".[1][3]
- Start steroid + steroid-sparing pathway with photoprotection; escalate early for MDA5 lung disease or bulbar involvement.[4]
Common errors
- Missing malignancy work-up in adult-onset DM.
- Ignoring MDA5/ILD risk in amyopathic presentations.
- Treating only the rash without muscle/systemic assessment.
- High-dose steroids alone forever without steroid-sparing plan.
- Missing dysphagia/respiratory muscle failure.
References5ShowHide
- [1]Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nature Reviews Disease Primers, 2021.PMID 34857798
- [2]DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. Journal of the American Academy of Dermatology, 2020.PMID 31279808
- [3]Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nature reviews. Rheumatology, 2024.PMID 38057474
- [4]Waldman R, DeWane ME, Lu J. Dermatomyositis: Diagnosis and treatment. Journal of the American Academy of Dermatology, 2020.PMID 31279813
- [5]Ashton C, Paramalingam S, Stevenson B, et al. Idiopathic inflammatory myopathies: a review. Internal medicine journal, 2021.PMID 34155760